Key result
Rivaroxaban shows no benefit over LMWH in preventing VTE after non-major orthopedic surgery.
Why the study?
Patients undergoing non-major orthopedic surgery face increased venous thromboembolism risk, and guideline-recommended LMWH is associated with low compliance and side effects, prompting evaluation of rivaroxaban as an alternative.
Does rivaroxaban prevent venous thromboembolism compared to low-molecular-weight heparin in patients undergoing non-major orthopedic surgery?
Meta-Analysis (n=5,101)
Randomized
Does rivaroxaban prevent venous thromboembolism compared to low-molecular-weight heparin in patients undergoing non-major orthopedic surgery?
Rivaroxaban and low-molecular-weight heparin demonstrate comparable efficacy and safety for thromboprophylaxis following non-major orthopedic surgery.
Answers are grounded in this paper and cite their sources.
Either agent is acceptable for VTE prophylaxis after non-major orthopedic surgery; meta-analysis confirms comparable efficacy and safety.
BACKGROUND: Patients undergoing non-major orthopedic surgery often face an increased risk of venous thromboembolism due to the necessity of immobilization postoperatively. Current guidelines commonly recommend the use of low-molecular-weight heparin (LMWH) for prophylaxis, but it is associated with low patient compliance and certain side effects. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the effectiveness and safety of rivaroxaban or LMWH for thromboprophylaxis following non-major orthopedic surgery. METHOD: Relevant literature was systematically searched in PubMed, Web of Science, Cochrane Library, and Embase from their inception to October 1, 2023, to evaluate the effectiveness and safety of rivaroxaban or LMWH in RCTs for thromboprophylaxis following non-major orthopedic surgery. RESULTS: A total of 5 randomized controlled trials involving 5,101 patients were included. There was no statistically significant difference in the preventive effect against venous thromboembolism (VTE) when using rivaroxaban or LMWH following non-major orthopedic surgery (RR 0.80; 95%CI 0.31 to 2.07). In terms of safety, there was also no statistically significant difference in the incidence of bleeding events in patients undergoing non-major orthopedic surgery when using rivaroxaban or LMWH (RR 1.15; 95% CI 0.75 to 1.76). CONCLUSION: In non-major orthopedic surgery, the risk of venous thromboembolism and bleeding complications is similar when using rivaroxaban or LMWH.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) conducted a meta-analysis in Non-major orthopedic surgery (n=5,101). Rivaroxaban vs. Low-molecular-weight heparin (LMWH) was evaluated on Venous thromboembolism (VTE) (RR 0.80, 95% CI 0.31 to 2.07, p=0.05). Rivaroxaban showed no significant difference compared to low-molecular-weight heparin in preventing venous thromboembolism following non-major orthopedic surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: